Table 13.
Cancer type for which PD-1/PD-L1 inhibitors can be used in clinical practice (in brackets are field application procedure for approval (as of April 2019)
| Cancer type | Biomarker | Treatment line | Agent |
|---|---|---|---|
| Melanoma | None | 1st line |
Nivolumab Pembrolizumab |
| Non-small cell lung cancer | PD-L1 positivea | 1st line |
Atezolizumab Durvalumab Nivolumab Pembrolizumab |
| Renal cell carcinoma | None | 2nd line | Nivolumab |
| 1st line |
(Avelumab) (Pembrolizumab) |
||
| Head and neck cancer | None | 2nd line |
Nivolumab Pembrolizumab |
| Gastric cancer | None | 3rd line | Nivolumab |
| Mesothelioma | None | 2nd line | Nivolumab |
| Urothelial cancer | None | 2nd line | Pembrolizumab |
| Merkel cell carcinoma | None | 1st line | Avelumab |
| Small cell lung cancer | None | 1st line | (Atezolizumab) |
| Breast cancer | PD-L1 positive | 1st line | (Atezolizumab) |
aWhen using alone as 1st line treatment